TITLE

Treatment and Prevention of Postherpetic Neuralgia

AUTHOR(S)

Dworkin, Robert H.; Schmader, Kenneth E.

PUB. DATE

April 2003

SOURCE

Clinical Infectious Diseases;4/1/2003, Vol. 36 Issue 7, p877

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

There have been 4 recent major advances in the treatment of postherpetic neuralgia (PHN) that are based on the results of randomized, controlled trials. These advances are the demonstrations that gabapentin, the lidocaine patch 5%, and opioid analgesics are efficacious in patients with PHN, and the report that nortriptyline and amitriptyline provide equivalent analgesic benefits for patients with PHN but that nortriptyline is better tolerated. The results of these clinical trials are briefly reviewed, and their implications for the treatment of patients with PHN are discussed. Despite these treatment advances, many patients remain refractory to current therapy, and the prevention of PHN has therefore become an important focus of current research. Research on administration of the varicella-zoster vaccine to prevent herpes zoster and on treatment of patients who have herpes zoster with combined antiviral and analgesic therapy to prevent PHN is discussed.

ACCESSION #

9423867

Tags: NEURALGIA -- Treatment;  CLINICAL trials

 

Related Articles

• Insufficient evidence to recommend topical lidocaine as first-line treatment for postherpetic neuralgia. Zakrzewska, Joanna M // Evidence-Based Dentistry;Sep2007, Vol. 8 Issue 3, p85 

  Data sourcesThe Cochrane Pain, Palliative and Supportive Care Group Trials Register, Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS (Latin American and Caribbean Health Sciences), SIGLE (System for Information on Grey Literature in Europe)(for conference proceedings) and...

• Convergence Moves CNV1014802 into Phase 2 Trial.  // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p26 

  The article reports on the phase 2 proof-of-concept study conducted by Cambridge, England-based Convergence Pharmaceuticals Ltd. for CNV1014802 which is a small-molecule, state-dependent sodium channel blocker for the treatment of pain associated with trigeminal neuralgia (TN).

• R&D Update.  // PharmaWatch: CNS;May2008, Vol. 7 Issue 5, p11 

  The article offers news briefs related to research and development in the pharmaceutical industry in the U.S. Depomed Inc. initiates the Phase III clinical trial that aims to evaluate Gabapentin GR for curing postherpetic neuralgia. Anesiva Inc. will start a Phase III trial that evaluates Adlea,...

• Depomed reports positive results from Phase III postherpetic neuralgia trial.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p10 

  The article reports on the positive results of the Phase III clinical trial conducted by pharmaceutical company Depomed Inc. Study shows that DM-1796 achieved a significant reduction in pain associated with post-herpetic neuralgia compared to placebo using the baseline observation carried...

• Depomed reports encouraging results from Phase III PHN trial.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p26 

  The article reports on the encouraging results of the Phase III postherpetic neuralgia (PHN) trial of Depomed Inc. It notes that the clinical trial conducted by the specialty pharmaceutical company has showed the efficacy of Gralise drug in treating PHN patients at least 65 years of age. It...

• Depomed: gabapentin faces limited potential after study failure.  // PharmaWatch: Monthly Review;Aug2007, Vol. 6 Issue 8, p14 

  No abstract available.

• Targeting Voltage-Gated Calcium Channels for Neuropathic Pain Management. Perret, Danielle; Luo, Z. David // Neurotherapeutics;Oct2009, Vol. 6 Issue 4, p679 

  Summary: Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiological functions. Pathological conditions leading to changes in their biophysical properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states. It is...

• Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions. Arning, Kathrin; Baron, Ralf // Neurotherapeutics;Oct2009, Vol. 6 Issue 4, p738 

  Summary: Classification of neuropathic pain has been based on disease entities, anatomical localization, or histological observations. Over the past decade, there has been an explosion in our understanding of the basic mechanisms of neuropathic pain. The exciting advances in basic science are...

• EpiCept: promising pain cream offers risky route to lucrative market.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p18 

  The article discusses the results of a Phase IIb trial in the U.S. that evaluated EpiCept Corp.'s NP-1 in post herpetic neuralgia. Results have shown that NP-1 has achieved its primary endpoint of superior pain relief. Despite such results, the company was expected to face problems over gaining...

Read the Article